Pharming Group N.V. ADS each representing 10 (PHAR)

Business: Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.

IPO Date: 23-Dec-2020

Pres, CEO & Exec. Director: Dr. Sijmen de Vries M.B.A., M.D., MBA

Consultant: Dr. Bruno M. L. Giannetti

Listing: NASDAQ: PHAR

Country: Netherlands

Headquarters: Leiden,

Website: https://www.pharming.com

Market cap: $506.02 Mln

Revenue (TTM): $178.26 Mln

Earnings (TTM): $9.90 Mln

Cash: $189.67 Mln

Total Debt: $157.79 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $6.10 - 11.60

Shares outstanding: 64,874,900

5 Years Aggregate:

• CFO: $251.02 Mln
• EBITDA: $109.54 Mln
• Net Profit: $27.75 Mln